- The data demonstrates the potential of Manual Dexterity Test and Konectom™ Smartphone-based technology to measure MS disease progression
- Retrospective analyzes using machine learning, artificial intelligence, and radiomics identify brain imaging patterns that may advance understanding of MS disease and lesion heterogeneity
- Two-level precision medicine models leveraging real-world data from the MS PATHS network provide new insights to enable more individualized predictions of treatment efficacy
CAMBRIDGE, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) — Biogen Inc. BIIB announced new multiple sclerosis (MS) disease measurement data and advanced analytics to be presented at the 38th European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress, October 26-28, 2022. These data underscore Biogen’s multi-pronged approach to conducting MS-related digital health research aimed at supporting the development of new treatments, individualizing care and advancing understanding of disease heterogeneity.
“Biogen is working to realize a future in which multidimensional data will be used to better characterize and monitor MS disease progression and predict therapy response at the individual level,” said Shibeshih Belachew, MD, Ph.D., Head of Science, Biogen Digital Health. “This year’s ECTRIMS presentations represent our ongoing digital health research and highlight advancements in the development of advanced measurement methods aimed at improving drug development and personalized care for better patient outcomes.”
Development of digital tools for more precise measurement of MS diseases
Several presentations at ECTRIMS highlight the technology’s potential to offer new possibilities in disease measurement through digital health technology tools. A poster examining the relationship between novel measurements from a technology-enhanced nine-hole peg test called the Manual Dexterity Test (MDT) included 3,525 patients and 44,394 MDT observations. Results suggest…
